Ergot alkaloids as pharmaceuticals: Status and prospects of commercial cultivation of ergot crop for natural alkaloids
Dr Borkar’s Laboratory and Research Centre, Endeavour Scientific Agriculture, 103, Prestige Point building, In front of Nashik Road Police Station, Nashik 422 101, India.
Review Article
Magna Scientia Advanced Biology and Pharmacy, 2023, 10(02), 080–089
Article DOI: 10.30574/msabp.2023.10.2.0083
Publication history:
Received on 13 November 2023; revised on 27 December 2023; accepted on 30 December 2023
Abstract:
Ergot is a plant disease symptom induced by a fungal pathogen of the genus Claviceps in grains of cereal crops, wherein the ergot alkaloids are produced in the cereal grains which are transformed into ergot sclerotia. The natural occurrence of ergot grains in cereal crops is dependent on the environmental factors conducive to ergot development. Under natural fungal infection, the ergot percent varies from 1.2 to 3.3 in the infected crops which hamper the yield or recovery of natural ergot alkaloids. Ergot alkaloids are specific pharmaceutical alkaloids used to treat certain ailments like migraines, induction of childbirth, and the control of postpartum bleeding in humans.
Ergot sclerotia contain about 0.15% to 0.5% alkaloids, with medicinally useful compounds. Annual world production of ergot alkaloids has been estimated at 5,000-8,000 kg of all ergopeptines (peptide ergot alkaloids) and 10,000-15,000 kg of lysergic acid, the latter being mainly used in the manufacture of semisynthetic derivatives. The greater part of this production occurs as a result of fermentation (around 60%) while field cultivation of triticale (a hybrid of wheat and rye) accounts for the balance. This is because the artificial cultivation of ergot sclerotia on a host crop plant is lacking as a business module. Due to the low recovery of ergot grains and ergot alkaloids under natural crop production conditions, commercial cultivation for ergot grains is discussed in this paper.
Keywords:
Ergot; Claviceps; Alkaloids; Pharmaceutical; Human ailments
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0